Anvisa Extends Implanon NXT Use to Five Years

Overview

• Anvisa updated its approval to allow the Implanon NXT etonogestrel implant to remain in place for up to five years based on clinical data reviewed by the regulator.
• The agency said the main study showed no pregnancies during the fourth and fifth years of use, forming the safety and efficacy basis for the extension.
• The decision permits insertion of the implant immediately after delivery and after first‑ and second‑trimester abortion under the conditions set by the regulator.
• Current users are advised to consult a health professional to confirm whether the new five‑year authorization applies to their specific device and to schedule individualized follow‑up rather than replacing implants immediately.
• The change aligns Brazil with recent regulatory moves in the United States, Canada and the United Kingdom and could reduce replacement procedures and strain on services as the method is rolled out through public and private health systems.